CVS Health (NYSE:CVS) has been assigned a $95.00 price objective by research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the pharmacy operator’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 33.78% from the company’s current price.
Other equities analysts have also issued research reports about the stock. Citigroup reduced their price target on shares of CVS Health from $88.00 to $87.00 and set a “neutral” rating for the company in a research report on Thursday, August 17th. Jefferies Group increased their price target on shares of CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a research report on Friday, September 15th. Wolfe Research lowered shares of CVS Health from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $89.00 to $82.00 in a research report on Monday, August 14th. Loop Capital set a $73.00 price target on shares of CVS Health and gave the company a “hold” rating in a research report on Monday. Finally, Robert W. Baird restated a “hold” rating and set a $77.00 price target on shares of CVS Health in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $86.35.
CVS Health (NYSE:CVS) opened at $71.01 on Monday. The firm has a market cap of $72,621.40, a PE ratio of 12.56, a P/E/G ratio of 1.23 and a beta of 0.89. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 1 year low of $66.45 and a 1 year high of $84.72.
In other news, EVP Thomas M. Moriarty sold 90,267 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.61, for a total value of $7,186,155.87. Following the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Larry J. Merlo sold 241,150 shares of the stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $83.07, for a total transaction of $20,032,330.50. Following the completion of the sale, the insider now directly owns 299,255 shares in the company, valued at $24,859,112.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 714,125 shares of company stock worth $58,119,381. Insiders own 0.61% of the company’s stock.
Several institutional investors have recently made changes to their positions in CVS. Vanguard Group Inc. raised its stake in CVS Health by 1.4% in the second quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock valued at $6,159,825,000 after purchasing an additional 1,056,265 shares in the last quarter. FMR LLC raised its stake in CVS Health by 22.0% in the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock valued at $2,425,920,000 after purchasing an additional 5,446,930 shares in the last quarter. Bank of America Corp DE raised its stake in CVS Health by 1.8% in the first quarter. Bank of America Corp DE now owns 22,411,957 shares of the pharmacy operator’s stock valued at $1,759,338,000 after purchasing an additional 398,999 shares in the last quarter. Northern Trust Corp raised its stake in CVS Health by 5.5% in the second quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock valued at $1,256,631,000 after purchasing an additional 807,639 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in CVS Health by 8.4% in the second quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock valued at $1,138,905,000 after purchasing an additional 1,100,373 shares in the last quarter. 82.24% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/06/cvs-health-cvs-pt-set-at-95-00-by-royal-bank-of-canada.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
What are top analysts saying about CVS Health Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CVS Health Corp and related companies.